You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 中国生物制药(1177.HK)涨5.29% 三日累涨约21%
格隆汇 02-25 10:25
格隆汇2月25日丨中国生物制药(1177.HK)涨5.29%,报8.95港元,三日累涨约21%,总市值1688亿港元。美银证券发表最新报告指,内地大型医疗公司的估值已创历史新高,虽然令投资者对医疗股看法转趋谨慎,但与其他领先的公司相比,认为中国生物制药今年能实现快速增长,故评级为“买入”评级。目标价由9.79港元上调至14.73港元,较昨收市价8.5港元有73.3%潜在升幅。报告称,中国生物制药持股的科兴利润贡献和疫苗资产被低估,认为目前估值尚未反映来自科兴利润贡献。从商业化的角度,科兴的疫苗发表时间较早,及更好的定价环境和产量,报告认为,科兴(Sinovac)疫苗较康希诺生物 等其他上市公司更令人放心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account